Xue Bai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xue Bai has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
Hongmei Tang
Department of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
8 shared publicationsShuangyang Li
Department of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
8 shared publicationsYujie Zhang
Department of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
6 shared publications- Yuting Pu
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan, China, 646600
6 shared publications Yuting Pu
The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Si Chuan, 646000, China
5 shared publicationsLingxue Wang
Department of Neurology, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University
4 shared publications
Latest Publications
- Open Access
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 20, 1836830
The research landscape of ferroptosis in ischemic stroke: a bibliometric analysis of the literature from 2017 to 2025 based on the WOS and PubMed databases
Background: Ischemic stroke is a leading cause of disability and mortality worldwide. Ferroptosis—an iron-dependent, lipid peroxidation-driven programmed cell death—has emerged as a key contributor to post-stroke neuronal injury, with research expanding rapidly since 2017. Objective: This study employs bibliometric methods to systematically analyze literature on ferroptosis in ischemic stroke from 2017 to 2025, aiming to elucidate the field’s development trajectory, research hotspots, emerging frontiers, and collaborative networks. Methods: Data were retrieved from the Web of Science Core Collection and PubMed, limited to English articles and reviews published between 2017 and 2025. For PubMed, an additional search was conducted to capture empirical studies on ferroptosis inhibitors. Bibliometric analyses were performed using VOSviewer, CiteSpace, and Bibliometrix R package. Results: A total of 646 WoS-indexed articles were analyzed. Annual publication output showed exponential growth. China, the United States, and India led in publication volume, with China accounting for over half of global output; international collaboration centered on China–US partnerships. Research hotspots focused on molecular mechanisms (GPX4, System Xc − , Nrf2/HO-1), key regulators (ACSL4, FSP1), and therapeutic strategies (ferroptosis inhibitors, natural compounds). Analysis of 64 PubMed-indexed studies on ferroptosis inhibitors revealed that China also dominated this area, with the National Natural Science Foundation of China as the primary funding source. Emerging frontiers indicate a shift from mechanistic studies toward clinical translation, including biomarker development, nano-targeted delivery, and neurovascular unit protection. Conclusion: From 2017 to 2025, research on ferroptosis in ischemic stroke has rapidly evolved from concept introduction and mechanistic exploration toward clinical translation. Bibliometric analysis delineates a clear trajectory and evolving knowledge framework. Future research will likely emphasize interdisciplinary integration, clinical translation, and personalized therapeutic strategies.
- 26 August 2026
- Published by Frontiers Media SA in Frontiers in Cellular Neuroscience
- Vol. 20, 1836830
Open AccessThe research landscape of ferroptosis in ischemic stroke: a bibliometric analysis of the literature from 2017 to 2025 based on the WOS and PubMed databases
Background: Ischemic stroke is a leading cause of disability and mortality worldwide. Ferroptosis—an iron-dependent, lipid peroxidation-driven programmed cell death—has emerged as a key contributor to post-stroke neuronal injury, with research expanding rapidly since 2017. Objective: This study employs bibliometric methods to systematically analyze literature on ferroptosis in ischemic stroke from 2017 to 2025, aiming to elucidate the field’s development trajectory, research hotspots, emerging frontiers, and collaborative networks. Methods: Data were retrieved from the Web of Science Core Collection and PubMed, limited to English articles and reviews published between 2017 and 2025. For PubMed, an additional search was conducted to capture empirical studies on ferroptosis inhibitors. Bibliometric analyses were performed using VOSviewer, CiteSpace, and Bibliometrix R package. Results: A total of 646 WoS-indexed articles were analyzed. Annual publication output showed exponential growth. China, the United States, and India led in publication volume, with China accounting for over half of global output; international collaboration centered on China–US partnerships. Research hotspots focused on molecular mechanisms (GPX4, System Xc − , Nrf2/HO-1), key regulators (ACSL4, FSP1), and therapeutic strategies (ferroptosis inhibitors, natural compounds). Analysis of 64 PubMed-indexed studies on ferroptosis inhibitors revealed that China also dominated this area, with the National Natural Science Foundation of China as the primary funding source. Emerging frontiers indicate a shift from mechanistic studies toward clinical translation, including biomarker development, nano-targeted delivery, and neurovascular unit protection. Conclusion: From 2017 to 2025, research on ferroptosis in ischemic stroke has rapidly evolved from concept introduction and mechanistic exploration toward clinical translation. Bibliometric analysis delineates a clear trajectory and evolving knowledge framework. Future research will likely emphasize interdisciplinary integration, clinical translation, and personalized therapeutic strategies.
- 4 August 2026
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 490, 126129
Brain frailty and EVT: Bridging the gap between statistical significance and clinical utility
- 4 August 2026
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 490, 126129
Brain frailty and EVT: Bridging the gap between statistical significance and clinical utility
- Open Access
- 2 July 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (3) , 1-14
TRPV1‑mediated central sensitisation: Core mechanisms of migraine chronification and novel targeted therapeutic strategies (Review)
Migraines are highly prevalent and disabling neurological disorders. Central sensitisation constitutes the core pathophysiological basis for its recurrent and chronic nature. Transient receptor potential vanilloid 1 (TRPV1), a key molecule in pain signalling, is not only involved in peripheral nociception, but is also highly expressed in central pain‑processing regions. TRPV1 directly contributes to the initiation and maintenance of central sensitisation, positioning it as a promising therapeutic target for migraine management. The present review systematically summarised the biological characteristics of TRPV1 and its associations with central sensitisation and migraines. The molecular mechanisms through which TRPV1 mediates central sensitisation are elaborated upon, including the regulation of neurotransmitter release, activation of glial cells, involvement in inflammatory responses and modulation of synaptic plasticity. Furthermore, the research progress and clinical challenges of TRPV1‑targeted strategies are discussed, including antagonists, agonists and genetic regulation. Lastly, the present study proposes future research directions at both basic and clinical levels, providing a novel molecular perspective on migraine pathogenesis and establishing a theoretical foundation for the development of targeted clinical therapies.
- 2 July 2026
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 58 (3) , 1-14
Open AccessTRPV1‑mediated central sensitisation: Core mechanisms of migraine chronification and novel targeted therapeutic strategies (Review)
Migraines are highly prevalent and disabling neurological disorders. Central sensitisation constitutes the core pathophysiological basis for its recurrent and chronic nature. Transient receptor potential vanilloid 1 (TRPV1), a key molecule in pain signalling, is not only involved in peripheral nociception, but is also highly expressed in central pain‑processing regions. TRPV1 directly contributes to the initiation and maintenance of central sensitisation, positioning it as a promising therapeutic target for migraine management. The present review systematically summarised the biological characteristics of TRPV1 and its associations with central sensitisation and migraines. The molecular mechanisms through which TRPV1 mediates central sensitisation are elaborated upon, including the regulation of neurotransmitter release, activation of glial cells, involvement in inflammatory responses and modulation of synaptic plasticity. Furthermore, the research progress and clinical challenges of TRPV1‑targeted strategies are discussed, including antagonists, agonists and genetic regulation. Lastly, the present study proposes future research directions at both basic and clinical levels, providing a novel molecular perspective on migraine pathogenesis and establishing a theoretical foundation for the development of targeted clinical therapies.
- Open Access
- 29 April 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1796295
Investigating the therapeutic mechanism of Puerarin in vascular dementia: an integrated approach combining network pharmacology and experimental validation
Background: Vascular dementia (VaD) is the second most common type of dementia after Alzheimer’s disease. Puerarin (PUE) is a natural compound isolated from Puerariae Lobatae Radix , plays an important role in treating neurodegenerative and neurovascular diseases. Studies have confirmed that Puerarin can reduce neuroinflammation and protect the blood-brain barrier (BBB). However, the precise mechanism by which PUE treats VaD remains to be elucidated. Objective: To investigate the therapeutic effect of Puerarin on VaD and its underlying molecular mechanisms. Materials and Methods: Cognitive performance was assessed using the behavioral testing. Hematoxylin and Eosin staining (H&E) and Nissl staining were employed to assess neuronal morphology in the hippocampus. Additionally, network pharmacology (NP) was used to identify putative bioactive compounds in PUE and candidate targets associated with VaD. Transmission electron microscopy (TEM), enzyme-linked immunosorbent assay (ELISA), quantitative PCR (qPCR), and Western blotting were used for experimental validation. To further interrogate pathway involvement, lipopolysaccharide (LPS), a Toll-like receptor 4 (TLR4) agonist, was administered, followed by repeated behavioral testing and molecular analyses. Results: Behavioral testing showed that PUE mitigated two-vessel occlusion (2VO)-induced cognitive deficits and reduced hippocampal neuronal injury. NP identified 17 putative active compounds and 100 overlapping targets between PUE and VaD. GO and KEGG enrichment analyses indicated that these targets were enriched in Toll-like receptor and NF-κB signaling, implicating an anti-neuroinflammatory mechanism. Experimental assays showed that PUE reduced TLR4 and myeloid differentiation primary response 88 (MyD88) expression, decreased nuclear factor-kappa-B p65 (NF-κB p65) phosphorylation, and lowered pro-inflammatory mediator levels. Importantly, the administration of the TLR4 agonist LPS effectively counteracted the therapeutic effects of Puerarin. Conclusion: Puerarin improves learning and cognitive abilities in VaD rats by inhibiting the TLR4/MyD88/NF-κB signaling pathway, thereby attenuating pathological alterations in the hippocampus, protecting the BBB integrity from cerebral ischemic damage, and exerting anti-neuroinflammatory effects.
- 29 April 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1796295
Open AccessInvestigating the therapeutic mechanism of Puerarin in vascular dementia: an integrated approach combining network pharmacology and experimental validation
Background: Vascular dementia (VaD) is the second most common type of dementia after Alzheimer’s disease. Puerarin (PUE) is a natural compound isolated from Puerariae Lobatae Radix , plays an important role in treating neurodegenerative and neurovascular diseases. Studies have confirmed that Puerarin can reduce neuroinflammation and protect the blood-brain barrier (BBB). However, the precise mechanism by which PUE treats VaD remains to be elucidated. Objective: To investigate the therapeutic effect of Puerarin on VaD and its underlying molecular mechanisms. Materials and Methods: Cognitive performance was assessed using the behavioral testing. Hematoxylin and Eosin staining (H&E) and Nissl staining were employed to assess neuronal morphology in the hippocampus. Additionally, network pharmacology (NP) was used to identify putative bioactive compounds in PUE and candidate targets associated with VaD. Transmission electron microscopy (TEM), enzyme-linked immunosorbent assay (ELISA), quantitative PCR (qPCR), and Western blotting were used for experimental validation. To further interrogate pathway involvement, lipopolysaccharide (LPS), a Toll-like receptor 4 (TLR4) agonist, was administered, followed by repeated behavioral testing and molecular analyses. Results: Behavioral testing showed that PUE mitigated two-vessel occlusion (2VO)-induced cognitive deficits and reduced hippocampal neuronal injury. NP identified 17 putative active compounds and 100 overlapping targets between PUE and VaD. GO and KEGG enrichment analyses indicated that these targets were enriched in Toll-like receptor and NF-κB signaling, implicating an anti-neuroinflammatory mechanism. Experimental assays showed that PUE reduced TLR4 and myeloid differentiation primary response 88 (MyD88) expression, decreased nuclear factor-kappa-B p65 (NF-κB p65) phosphorylation, and lowered pro-inflammatory mediator levels. Importantly, the administration of the TLR4 agonist LPS effectively counteracted the therapeutic effects of Puerarin. Conclusion: Puerarin improves learning and cognitive abilities in VaD rats by inhibiting the TLR4/MyD88/NF-κB signaling pathway, thereby attenuating pathological alterations in the hippocampus, protecting the BBB integrity from cerebral ischemic damage, and exerting anti-neuroinflammatory effects.
- 19 April 2026
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 486, 125926
Beyond biology: Key blind spots in predicting futile recanalisation
- 19 April 2026
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 486, 125926
Beyond biology: Key blind spots in predicting futile recanalisation
- 15 April 2026
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 112, 112207
AI improves anesthesia consultation efficiency, but clinical applicability and patient acceptance remain to be validated
- 15 April 2026
- Published by Elsevier in Journal of Clinical Anesthesia
- Vol. 112, 112207
AI improves anesthesia consultation efficiency, but clinical applicability and patient acceptance remain to be validated
- 11 March 2026
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 108, 112819
Adopting a "dual-track" inclusion strategy aligned with DSM-5 clinical diagnosis to enhance the clinical translatability of study findings
- 11 March 2026
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 108, 112819
Adopting a "dual-track" inclusion strategy aligned with DSM-5 clinical diagnosis to enhance the clinical translatability of study findings
- Open Access
- 6 March 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 237, 111806
The role of the Toll-like receptor family in stroke: functions, mechanisms and therapeutic targets
- 6 March 2026
- Published by Elsevier in Brain Research Bulletin
- Vol. 237, 111806
Open AccessThe role of the Toll-like receptor family in stroke: functions, mechanisms and therapeutic targets
- Open Access
- 16 January 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (1) , e70503
Moving Beyond Population‐Level Analyses to Characterize Individual Heterogeneity in CMAP Responses Would Enhance the Assessment of Its Clinical Utility
- 16 January 2026
- Published by Wiley in European Journal of Neurology
- Vol. 33 (1) , e70503
Open AccessMoving Beyond Population‐Level Analyses to Characterize Individual Heterogeneity in CMAP Responses Would Enhance the Assessment of Its Clinical Utility